Upstream Bio initiated with a Buy at TD Cowen
The Fly

Upstream Bio initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Upstream Bio (UPB) with a Buy rating. The firm says the company’s verekitug is a “differentiated fast follower” with greater potency and extended dosing intervals versus Tezspire. Tge Phase 1 data have shown “rapid, deep, and sustained effects” on asthma biomarkers, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App